Amplia Therapeutics Limited (ATX.AX)
AUD 0.08
(-2.35%)
AUD 0.08
(-2.35%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 4.45 Million | 1.18 Million | 1.98 Million | 1.53 Million | 34.22 Thousand | 50.47 Thousand |
| Cost of Revenue | 441.99 Thousand | 73.36 Thousand | 3209.00 | 672.00 | 801.00 | 1590.00 |
| Gross Profit | 4.01 Million | 1.11 Million | 1.98 Million | 1.53 Million | 33.42 Thousand | 48.88 Thousand |
| Operating Expenses | 8.43 Million | 7.4 Million | 5.62 Million | 3.87 Million | 2.25 Million | 1.92 Million |
| Selling, General and Administrative Expenses | 2.68 Million | 2.71 Million | 1.85 Million | 1.66 Million | 1.18 Million | 1.24 Million |
| Research and Development Expenses | 5.8 Million | 4.68 Million | 3.77 Million | 2.21 Million | 1.07 Million | 678.41 Thousand |
| Other Expenses | -58.95 Thousand | 1.18 Million | 1.98 Million | 1.59 Million | 34.22 Thousand | 50.47 Thousand |
| Cost and Expenses | 8.87 Million | 7.47 Million | 5.62 Million | 3.87 Million | 2.25 Million | 1.92 Million |
| Operating Income | -4.42 Million | -7.47 Million | -5.62 Million | -3.87 Million | -2.25 Million | -1.92 Million |
| Interest Expense | 78.48 Thousand | 53.84 Thousand | 1150.00 | - | - | - |
| Income Tax Expense | -4.43 Million | -1.14 Million | -1.98 Million | -1.53 Million | -34.22 Thousand | -50.47 Thousand |
| Earnings before Tax | -8.94 Million | -7.39 Million | -5.62 Million | -3.81 Million | -2.25 Million | -1.92 Million |
| Net Income | -4.5 Million | -6.24 Million | -3.64 Million | -2.28 Million | -2.21 Million | -1.86 Million |
| Earnings Per Share Basic | -0.02 | -0.03 | -0.02 | -0.02 | -0.04 | -0.04 |
| Earnings Per Share Diluted | -0.02 | -0.03 | -0.02 | -0.02 | -0.04 | -0.04 |
| Weighted Average Shares Outstanding | 194.01 Million | 193.97 Million | 145.54 Million | 95.7 Million | 52.95 Million | 43.43 Million |
| Weighted Average Shares Outstanding (Diluted) | 194 Million | 193.97 Million | 145.54 Million | 95.7 Million | 52.95 Million | 43.43 Million |
| Gross Margin | 0.90 | 0.94 | 1.00 | 1.00 | 0.98 | 0.97 |
| EBIT Margin | -1.02 | -6.22 | -2.84 | -2.53 | -65.98 | -38.13 |
| Profit Margin | -1.01 | -5.25 | -1.84 | -1.49 | -64.85 | -37.05 |
| EBITDA | -4.55 Million | -7.26 Million | -3.64 Million | -2.33 Million | -2.22 Million | -1.88 Million |
| Earnings Before Tax Margin | -0.99 | -6.28 | -2.84 | -2.53 | -66.00 | -38.16 |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 4.45 Million | 2 Million | 2.44 Million | 1.18 Million | -579.89 Thousand | 1.76 Million |
| Cost of Revenue | 86.14 Thousand | 330.57 Thousand | 42.94 Thousand | 73.36 Thousand | 44.37 Thousand | 28.99 Thousand |
| Gross Profit | 4.36 Million | 1.67 Million | 2.4 Million | 1.11 Million | -624.27 Thousand | 1.74 Million |
| Operating Expenses | 8.93 Million | 5.01 Million | 3.56 Million | 7.4 Million | 2.75 Million | 4.64 Million |
| Selling, General and Administrative Expenses | - | 1.42 Million | 1.37 Million | - | 1.59 Million | 1.12 Million |
| Research and Development Expenses | - | 3.61 Million | 2.19 Million | - | 1.15 Million | 3.52 Million |
| Other Expenses | - | -23.35 Thousand | - | 1.18 Million | - | - |
| Cost and Expenses | 9.02 Million | 5.34 Million | 3.6 Million | 7.47 Million | 2.79 Million | 4.67 Million |
| Operating Income | -9.02 Million | -3.34 Million | -3.6 Million | -7.47 Million | -2.79 Million | -4.67 Million |
| Interest Expense | 78.48 Thousand | 31.84 Thousand | 46.63 Thousand | 53.84 Thousand | 37.7 Thousand | 16.14 Thousand |
| Income Tax Expense | -4.43 Million | -1.98 Million | -2.44 Million | -1.14 Million | 579.89 Thousand | -1.72 Million |
| Earnings before Tax | -8.94 Million | -3.37 Million | -3.57 Million | -7.39 Million | -2.75 Million | -4.64 Million |
| Net Income | -4.5 Million | -3.37 Million | -1.12 Million | -6.24 Million | -3.33 Million | -2.91 Million |
| Earnings Per Share Basic | - | -0.02 | -0.01 | - | -0.02 | -0.01 |
| Earnings Per Share Diluted | - | -0.02 | -0.01 | - | -0.02 | -0.01 |
| Weighted Average Shares Outstanding | 199.61 Million | 193.78 Million | 199.61 Million | 193.97 Million | 199.61 Million | 199.55 Million |
| Weighted Average Shares Outstanding (Diluted) | 199.61 Million | 194 Million | 199.61 Million | 193.97 Million | 199.61 Million | 199.55 Million |
| Gross Margin | 0.98 | 0.84 | 0.98 | 0.94 | 1.08 | 0.98 |
| EBIT Margin | - | -1.72 | -1.46 | - | 4.75 | -2.63 |
| Profit Margin | -1.01 | -1.68 | -0.46 | -5.25 | 5.74 | -1.65 |
| EBITDA | - | -3.44 Million | -3.56 Million | - | -2.75 Million | -4.64 Million |
| Earnings Before Tax Margin | -2.03 | -1.67 | -1.47 | -6.28 | 4.82 | -2.64 |
300969
LREN3
JACO
BIOQ
MMNNF
BNDSF